With these new enrollment numbers, 70 events needed for the interim analysis now estimated to occur between 5/1/2015 [10% NeuVax recurrence] and 12/1/2015 [5% NeuVax recurrence rate] I personally believe if NeuVax yields a 50% reduction in DFS or better at the interim analysis it would be hard for the FDA to not grant early access with NeuVax's superior safety profile! Posted this on Yahoo - don't think there's a long left on that board!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.